April 2026 FDA Recall Duloxetine by Breckenridge Pharmaceutical, Inc.
D-0522-2026 - CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

This Class II drug recall was voluntarily initiated by Breckenridge Pharmaceutical, Inc. on April 21, 2026 for the product Duloxetine. The FDA reported the reason for recall as cgmp deviations; presence of n-nitroso-duloxetine impurity above the fda recommended limit. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0522-2026

Reason for Recall
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Initiated
04-21-2026
Reported
05-13-2026
Quantity
165,761 90-count bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Breckenridge Pharmaceutical, Inc.
Nationwide in the USA
Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical Eurpoe S.L., Martorelles, (Barcelona), Spain, Dist. by. Breckenridge Pharmaceutical, Inc., Berkely Heights, NJ 07922, NDC 51991-748-90.

Batch or Lot Expiration Information

Lot# Lot: 241069C, Exp 05/31/2027